Xspray Pharma
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Gunnar Asplunds Alle 32, Solna, Stockhol...Phone Number
+46 87303700Website
www.xspraypharma.comRevenue
$7.9 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Xspray Pharma
Xspray Pharma AB specializes in developing innovative, patented amorphous product candidates that enhance existing protein kinase inhibitors (PKIs) for cancer treatment. Their unique technology allows them to market these improved drugs as soon as the original patents expire, providing a significant opportunity in a multi-billion dollar market. The company aims to offer patients better treatment options compared to generics, retaining profile advantages even after the original drugs' secondary patents expire. With a strong pipeline and a reproducible development process, Xspray is well-positioned to capitalize on the potential of over 80 US-marketed PKIs.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xspray Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Xspray Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Xspray Pharma has new funding data
Website visits: Recent activity has been detected on your website
Xspray Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Xspray Pharma launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Xspray Pharma
Click to see if Xspray Pharma had a recent Job posting/layoffs
Check out if Xspray Pharma is spiking on competitors!
Earning: See what the market has to say on Xspray Pharma recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Xspray Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xspray Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xspray Pharma.
Xspray Pharma Tech Stack
A closer look at the technologies used by Xspray Pharma
See more technologies
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Promotion
Executive Move
Executive Moves, Promotion
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
Xspray Pharma News & Media
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology to develop enhanced cancer therapies, today announced significant progress following a productive meeting with the U.S. Food and Drug Administration (FDA). The company plans to resubmit its New Drug Application (NDA) for Dasynoc in Q4 2024, incorporating feedback from the Complete Response Letter (CRL) issued by FDA in July 2024. If the FDA sets aScientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology
STOCKHOLM--(BUSINESS WIRE)--A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap™ technology improves the bioavailability and reduces variability of two important tyrosine kinase inhibitors (TKIs), Dasynoc™ (XS004, dasatinib) and XS005 (sorafenib). Reduced variability generally leads to better safety and can potentially increase treatment effectiveness for patients, ensuring prescribers that their seriously ill patientsXspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024
Xspray Pharma AB appointed Linda Glimberg as the company?s COO , a newly established role. Linda Glimberg already part of the Xspray Pharma team as consulting Senior Vice President Legal and will be...Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a Swedish pharmaceutical company which uses its innovative Hynap technology to develop 505(b)(2) improved versions of marketed drugs for the treatment of cancer announced today the online publication of its abstract titled “Frequency of Comedication of Proton Pump Inhibitors with Crystalline Dasatinib in Chronic Myeloid Leukemia and Effects on TKI-Bioavailability” for presentation at the upcoming American Society of
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xspray Pharma
Sign Up For FreeTo access detailed company insights
Xspray Pharma AB specializes in developing innovative, patented amorphous product candidates that enhance existing protein kinase inhibitors (PKIs) for cancer treatment. Their unique technology allows them to market these improved drugs as soon as the original patents expire, providing a significant opportunity in a multi-billion dollar market. The... Read More
